Answers are grounded in this paper and cite their sources.
Case report demonstrates ivosidenib effects on progression-free survival in high-grade astrocytomas, suggesting potential benefits for treatment.
Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.
No takes yet. Share an insight, caveat, or question.
Adjei et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: